In order to test CCR9 inhibition in a nonprophylactic regimen, that is, starting treatment during the onset of colitis, 16-week-old mdr1a−/− mice were randomized to receive either CCX282-B or vehicle. The gene discussed is CCR9; the disease is colitis.